PHASE-II EVALUATION OF DOXORUBICIN PLUS CISPLATIN IN ADVANCED THYROID-CANCER - A SOUTHEASTERN-CANCER-STUDY-GROUP TRIAL
- 1 March 1986
- journal article
- research article
- Vol. 70 (3) , 405-407
Abstract
Twenty-two evaluable patients with all cell types of advanced thyroid cancer were treated with the combination of doxorubicin (60 mg/m2) plus cisplatin (60 mg/m2). There were two brief partial remissions (9.1%). There was considerable toxicity, with one drug-related death. Combination chemotherapy as given in this study was not effective for this patient population.This publication has 4 references indexed in Scilit:
- COMBINATION CHEMOTHERAPY OF METASTATIC THYROID-CANCER - PHASE-II STUDY1983
- CURRENT STATUS OF CHEMOTHERAPY IN THE TREATMENT OF ADVANCED-CARCINOMA OF THE THYROID-GLAND1981
- Malignant lymphomas and undifferentiated small cell carcinoma of the thyroid: a clinicopathological review in the light of the Kiel classification for malignant lymphomasHistopathology, 1978
- CLINICAL RESPONSE AND TOXICITY WITH CIS-DICHLORODIAMMINEPLATINUM(II) IN CHILDREN1977